Genetic control of anticoagulation
- 27 February 1999
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 353 (9154), 688-689
- https://doi.org/10.1016/s0140-6736(98)00326-2
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Multicentre randomised study of computerised anticoagulant dosageThe Lancet, 1998
- Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased riskThe Lancet, 1998
- Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapyBritish Journal of Haematology, 1997
- A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.JCI Insight, 1996
- Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)The Lancet, 1996
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Anticoagulant-related bleeding: Clinical epidemiology, prediction, and preventionAmerican Journal Of Medicine, 1993
- Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.BMJ, 1987